UNAIDS Urges U.S. to Reconsider South Africa HIV Funding Withdrawal 
Gold Prices Slip From 10-Week High as Fed and Hormuz Risks Shape Outlook 
S&P 500 Hits Record High as Soft Inflation Data Eases Fed Rate Hike Fears 
Antofagasta Shares Drop 5% as Miner Cuts 2026 Copper Production Forecast 
Asian Currencies Steady Ahead of US CPI as Oil Prices Rise 
Nvidia Eyes $3 Billion Investment in SoftBank-Backed AI Data Center 
Paramount Weighs CNN Sale as $110B Warner Bros. Discovery Deal Faces Antitrust Fight 
Asian Stocks Rally as Cooling US Inflation Boosts Fed Rate Outlook 
Maersk Raises 2026 Earnings Outlook as Shipping Profits Beat Expectations 
GSK Unveils $2.52 Billion Cost-Cutting Plan to Accelerate Drug Pipeline 
AstraZeneca Q2 Earnings Beat Forecasts as Oncology Growth Supports 2026 Outlook 
France Keeps Top Health Alert as Officials Brace for Another Heatwave 
Australia’s Corporate Leaders Face Parliament Over KPMG Client Data Scandal 
J.P. Morgan Upgrades SanDisk, Sets $2,250 Price Target on AI NAND Growth 
Aviva First-Half Operating Profit Jumps 24% as Direct Line Deal Boosts Growth 
NIH Infectious Disease Leadership Shake-Up Raises Concerns Amid Ebola, Hantavirus Outbreaks 
Add as a preferred source on Google
SK bioscience Co. will invest $1.79 billion by 2027 to expand its contract manufacturing capabilities to strengthen its readiness for the next pandemic, expand its overseas operations, and seize new business opportunities.
The proposed investment is twice the amount the company had spent in the past five years.
Of the total investment, t half would be spent on research and development (R&D) and the construction of a new R&D campus in Songdo, Incheon, which is expected to be completed in 2025.
SK bioscience has manufactured the COVID-19 vaccines of AstraZeneca and Novavax in South Korea under a partnership deal.
The company is seeking to ink deals with major pharmaceutical companies within the year, according to SK bioscience CEO Ahn Jae-yong.
"A deal could come as early as within the first half of this year," he said.
Also, the company has been looking for a possible merger deal in the United States in the field of cell and gene therapy.
The company swung to a deficit for the January-March period as waning demand led to a drop in the production of licensed COVID-19 vaccines. Its loss amounted to 29.2 billion won, compared with a profit of 23.8 billion won a year ago.
Ahn expected the company to make a turnaround in three years after investing aggressively in building up the foundations for future growth.
